Results

Bionano Genomics Inc.

01/12/2026 | Press release | Distributed by Public on 01/12/2026 07:16

Bionano Reports Preliminary Fourth Quarter and Full-Year 2025 Results (Form 8-K)

Bionano Reports Preliminary Fourth Quarter and Full-Year 2025 Results
SAN DIEGO, January 12, 2026 - Bionano Genomics, Inc. (NASDAQ: BNGO) today reported certain unaudited preliminary financial results and commercial highlights for the fourth quarter and fiscal year ended December 31, 2025.
"2025 was a pivotal year for Bionano. We transformed our business model to focus on routine users of our optical genome mapping (OGM) solutions, improved our financial profile with reduced cash burn and improved gross margins, and expanded the use and adoption of OGM both in the U.S. and internationally," commented Erik Holmlin, PhD, president and chief executive officer of Bionano. "We saw important reimbursement progress with the establishment of a second category I CPT code for OGM, this time in constitutional genetic disorders and a 47% increase in payment determination for the category I CPT code for OGM use in hematologic malignancies. We also saw significant expansion in the body of published clinical research evidence in support of using OGM as an alternative to traditional cytogenetic methods, with continued growth both in peer-reviewed publications and reported clinical research genomes. Our teams launched a major upgrade to our software and compute platforms, among other product improvements. As a result, we are entering 2026 with a strong foundation and pipeline of demand."
Fourth Quarter 2025 Preliminary, Unaudited Financial and Business Results
For the three-month period ended December 31, 2025:

•
Total revenue is expected to be in the range of $7.8 million to $8.0 million, which is at the upper end of guidance and represents a decrease in the range of 2% to 4% year-over-year.

•
Nanochannel array flowcells sold in the fourth quarter of 2025 is expected to be 7,554.

•
Installed 9 new OGM systems.
Full Year 2025 Preliminary, Unaudited Financial and Business Results
For the twelve-month period ended December 31, 2025:

•
Total revenue is expected to be in the range of $28.4 million to $28.6 million, which is also within the annual revenue guidance provided and represents a decrease in the range of 7% to 8% year-over-year.

•
Nanochannel array flowcells sold in the full year 2025 is expected to be 30,171.

•
Installed 32 new OGM systems, which after exchange or return of systems, resulted in an installed base of 387 OGM systems at year-end 2025, compared to 371 at year-end 2024.



Cash, cash equivalents, available-for-sale securities, and restricted short-term investments were approximately $29.6 million as of December 31, 2025, of which $10.3 million is subject to certain restrictions.
Bionano is in the process of completing its customary year-end close and review procedures and has not completed preparation of its financial statements for the fourth quarter of 2025 or for the full year ended December 31, 2025. The financial performance measures presented in this press release for the fourth quarter of 2025 and for the year ended December 31, 2025 are preliminary and unaudited, are based on management's initial review of the information presented, and are thus inherently uncertain and subject to change as Bionano completes its end-of-period reporting process and related activities for the fourth quarter of 2025 and the full year ended December 31, 2025. During the course of the preparation of Bionano's consolidated financial statements and related notes as of and for the year ended December 31, 2025, Bionano's independent registered public accountants may identify items that could cause final reported results to be materially different from the preliminary estimates presented in this press release. Additional information and disclosures would be required for a more complete understanding of Bionano's financial position and results of operations as of and for the fourth quarter and full year ended December 31, 2025. Accordingly, undue reliance should not be placed on this preliminary information.
About Bionano

Bionano is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company's mission is to transform the way the world sees the genome through optical genome mapping (OGM) solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. The Company also offers an industry-leading, platform-agnostic genome analysis software solution, and nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. Through its Lineagen, Inc. d/b/a Bionano Laboratories business, the Company also offers OGM-based diagnostic testing services.
For more information, visit www.bionano.com or www.bionanolaboratories.com.
Bionano's products are for research use only and not for use in diagnostic procedures.


Bionano Genomics Inc. published this content on January 12, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on January 12, 2026 at 13:16 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]